KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Cash & Equivalents (2016 - 2025)

Pacira BioSciences has reported Cash & Equivalents over the past 16 years, most recently at $158.5 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $158.5 million for Q4 2025, down 42.72% from a year ago — trailing twelve months through Dec 2025 was $158.5 million (down 42.72% YoY), and the annual figure for FY2025 was $158.5 million, down 42.72%.
  • Cash & Equivalents for Q4 2025 was $158.5 million at Pacira BioSciences, up from $147.6 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for PCRX hit a ceiling of $585.6 million in Q4 2021 and a floor of $35.5 million in Q1 2023.
  • Median Cash & Equivalents over the past 5 years was $150.4 million (2023), compared with a mean of $183.7 million.
  • Biggest five-year swings in Cash & Equivalents: surged 485.83% in 2021 and later tumbled 84.32% in 2023.
  • Pacira BioSciences' Cash & Equivalents stood at $585.6 million in 2021, then plummeted by 82.22% to $104.1 million in 2022, then skyrocketed by 47.21% to $153.3 million in 2023, then surged by 80.55% to $276.8 million in 2024, then crashed by 42.72% to $158.5 million in 2025.
  • The last three reported values for Cash & Equivalents were $158.5 million (Q4 2025), $147.6 million (Q3 2025), and $300.5 million (Q2 2025) per Business Quant data.